URGN news

Latest 2 stories · newest Nov 4, 2026

URGN

UroGen Reports $68M Q3 ZUSDURI Revenue, 35% YoY Growth

UroGen's ZUSDURI generated $68M in revenue in Q3 2026, while the FDA accepted the NDA for UGN-103 for review with a PDUFA goal date of June 14, 2027.

Earnings Nov 4, 2026 sentiment +0.60 SEC filing ↗

URGN

UroGen Files Articles of Association for Compliance

UroGen Pharma Ltd. filed its Articles of Association as an exhibit to satisfy corporate governance requirements. This filing outlines specific operational definitions and terms necessary to maintain NASDAQ listing standards.

Regulatory Jun 23, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same URGN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/URGN/newsSTART FREE